Jefferies lifted its price target on Buy-rated Biogen (NASDAQ: BIIB) from $270 to $300 following solid Q3 results.

"BIIB ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE